Last updated: 2026-10-19 22:33:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Fulgent Genetics, Inc. (FLGT) operates in the SERVICES-MEDICAL LABORATORIES sector and is listed on NASDAQ. The stock is currently priced at $20.11, with a market capitalization of $545.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $13.46 to $31.04. This page covers its latest market performance, valuation, price trends and company information.
$545.08M | |
$19.89 | |
$189.89 | |
$2.73 | |
$19.81 | |
164.49K | |
306.36K | |
-- | |
$31.04 | |
$13.46 | |
-- | |
-- |
Fulgent Genetics, Inc. (FLGT) is trading at $20.12 in after-hours trading as of 2026-10-19 20:39:00, up 1.54% ($0.30) from the regular-session close of $19.81.
After-hours trading shows how investors are pricing FLGT after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Fulgent Genetics, Inc. (FLGT) moved from $20.82 to $20.11, representing a decline of 3.41% ($0.71).
The stock traded between $19.73 and $21.80 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 292.33 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 37.8%
FLGT is currently trading at $20.11, placing it 37.8% of the way from its 52-week low of $13.46 to its 52-week high of $31.04. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in the laboratory services business and the therapeutic development business. The laboratory services business, which generates key revenue, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue, and Foreign.
| Industry | SERVICES-MEDICAL LABORATORIES |
| Employees | 1315 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Fulgent Genetics, Inc. (FLGT) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.